BACKGROUND AND PURPOSE: Several studies suggest that various types of cellular therapies enhance recovery after stroke in animal models. IA-based delivery of cells to the brain is under investigation for stroke, but it is unknown whether cells are injured as a result of being injected through a catheter or exposed to iodinated contrast medium or solutions containing heparin. MATERIALS AND METHODS: We assessed the effect of catheterization with the Excelsior SL-10 catheter or exposure to heparin or iodine contrast on human bone marrow MNCs. Viability and cell injury were assessed by trypan blue exclusion, caspase-3 activity, and lipid peroxidation. Cellular function of MNCs was assessed by their production and release of VEGF, IL-10, and IGF-1. RESULTS: Flow rates of 10 million cells from 0.5 to 2 mL/min did not alter MNC viability; however, 5 mL/min of MNCs did reduce viability by 19%. Iodine and low-dose heparin exposure did not affect cell viability; however, high-dose heparin was cytotoxic. Catheter delivery at 2 mL/min did not affect levels of VEGF, IL-10, or IGF-1. CONCLUSIONS: MNCs do not appear to be damaged by heparin, iodine contrast, and the Excelsior SL-10 catheter at flow rates up to 2 mL/min. However, higher flow rates did reduce viability, and high-dose heparin did cause cell death.
BACKGROUND AND PURPOSE: Several studies suggest that various types of cellular therapies enhance recovery after stroke in animal models. IA-based delivery of cells to the brain is under investigation for stroke, but it is unknown whether cells are injured as a result of being injected through a catheter or exposed to iodinated contrast medium or solutions containing heparin. MATERIALS AND METHODS: We assessed the effect of catheterization with the Excelsior SL-10 catheter or exposure to heparin or iodine contrast on human bone marrow MNCs. Viability and cell injury were assessed by trypan blue exclusion, caspase-3 activity, and lipid peroxidation. Cellular function of MNCs was assessed by their production and release of VEGF, IL-10, and IGF-1. RESULTS: Flow rates of 10 million cells from 0.5 to 2 mL/min did not alter MNC viability; however, 5 mL/min of MNCs did reduce viability by 19%. Iodine and low-dose heparin exposure did not affect cell viability; however, high-dose heparin was cytotoxic. Catheter delivery at 2 mL/min did not affect levels of VEGF, IL-10, or IGF-1. CONCLUSIONS: MNCs do not appear to be damaged by heparin, iodine contrast, and the Excelsior SL-10 catheter at flow rates up to 2 mL/min. However, higher flow rates did reduce viability, and high-dose heparin did cause cell death.
Authors: Sean I Savitz; Jonathan Dinsmore; Julian Wu; Galen V Henderson; Philip Stieg; Louis R Caplan Journal: Cerebrovasc Dis Date: 2005-06-21 Impact factor: 2.762
Authors: Miranda Brenneman; Sushil Sharma; Matthew Harting; Roger Strong; Charles S Cox; Jarek Aronowski; James C Grotta; Sean I Savitz Journal: J Cereb Blood Flow Metab Date: 2009-09-23 Impact factor: 6.200
Authors: Michael J Lipinski; Giuseppe G L Biondi-Zoccai; Antonio Abbate; Reena Khianey; Imad Sheiban; Jozef Bartunek; Marc Vanderheyden; Hyo-Soo Kim; Hyun-Jae Kang; Bodo E Strauer; George W Vetrovec Journal: J Am Coll Cardiol Date: 2007-10-15 Impact factor: 24.094
Authors: Matthew T Harting; Charles S Cox; Mary-Clare Day; Peter Walker; Adrian Gee; Miranda M Brenneman; James C Grotta; Sean I Savitz Journal: Cytotherapy Date: 2009 Impact factor: 5.414
Authors: Congqi Yan; Michael E Mackay; Kirk Czymmek; Radhika P Nagarkar; Joel P Schneider; Darrin J Pochan Journal: Langmuir Date: 2012-03-27 Impact factor: 3.882
Authors: Paulo Henrique Rosado-de-Castro; Pedro Moreno Pimentel-Coelho; Lea Mirian Barbosa da Fonseca; Gabriel Rodriguez de Freitas; Rosalia Mendez-Otero Journal: Stem Cells Dev Date: 2013-04-25 Impact factor: 3.272